Genep Inc. has prepared and tested Imidazole compounds acting as sodium channel protein type 8 subunit α (SCN8A; Nav1.6) blockers reported to be useful for the treatment of epilepsy.

XEN901 is a potent, selective Nav1.6 sodium channel inhibitor being developed by Xenon for the treatment of epilepsy, including treatment resistant adult focal seizures and rare, pediatric forms ...

A multi-platform antibody discovery approach (phage display, llama immunization) has enabled TetraGenetics to identify functional anti-Nav1.8 antibodies that selectively inhibit Nav1.8 currents in ...

BioWorld - Thursday, July 3, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Genep discovers new Nav1.6 blockers To read ...